1.
Neurology: a Queen Square textbook. (Wiley Blackwell, 2016).
2.
McCarthy, R. A. & Warrington, E. K. Cognitive neuropsychology: a clinical introduction. (Academic Press, Inc, 1990).
3.
Rossor, M. & Growdon, J. H. The dementias 2. (Butterworth Heinemann/Elsevier, 2007).
4.
Hodges, J. R. Cognitive assessment for clinicians. (Oxford University Press, 2017).
5.
Principles of neural science. (McGraw Hill Medical, 2013).
6.
Husain, M. Oxford textbook of cognitive neurology and dementia. (Oxford University Press, 2016).
7.
Alzheimer’s Facts and Figures Report | Alzheimer’s Association. https://www.alz.org/alzheimers-dementia/facts-figures.
8.
Selkoe, D. J. & Hardy, J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Molecular Medicine 8, 595–608 (2016).
9.
Dubois, B. et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. The Lancet Neurology 13, 614–629 (2014).
10.
Loy, C. T., Schofield, P. R., Turner, A. M. & Kwok, J. B. Genetics of dementia. The Lancet 383, 828–840 (2014).
11.
Karran, E. & Hardy, J. Antiamyloid Therapy for Alzheimer’s Disease — Are We on the Right Road? New England Journal of Medicine 370, 377–378 (2014).
12.
Johnson, K. A., Fox, N. C., Sperling, R. A. & Klunk, W. E. Brain Imaging in Alzheimer Disease. Cold Spring Harbor Perspectives in Medicine 2, a006213–a006213 (2012).
13.
Ross, C. A. et al. Huntington disease: natural history, biomarkers and prospects for therapeutics. Nature Reviews Neurology 10, 204–216 (2014).
14.
Bates, G. P. et al. Huntington disease. Nature Reviews Disease Primers (2015) doi:10.1038/nrdp.2015.5.
15.
Wild, E. J. & Tabrizi, S. J. Therapies targeting DNA and RNA in Huntington’s disease. The Lancet Neurology 16, 837–847 (2017).
16.
Carroll, J. B., Bates, G. P., Steffan, J., Saft, C. & Tabrizi, S. J. Treating the whole body in Huntington’s disease. The Lancet Neurology 14, 1135–1142 (2015).
17.
Tabrizi, S. J. et al. Biological and clinical changes in premanifest and early stage Huntington’s disease in the TRACK-HD study: the 12-month longitudinal analysis. The Lancet Neurology 10, 31–42 (2011).
18.
Tabrizi, S. J. et al. Potential endpoints for clinical trials in premanifest and early Huntington’s disease in the TRACK-HD study: analysis of 24 month observational data. The Lancet Neurology 11, 42–53 (2012).
19.
Tabrizi, S. J. et al. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington’s disease in the TRACK-HD study: analysis of 36-month observational data. The Lancet Neurology 12, 637–649 (2013).
20.
Jones, L., Houlden, H. & Tabrizi, S. J. DNA repair in the trinucleotide repeat disorders. The Lancet Neurology 16, 88–96 (2017).
21.
Rossor, M. et al. Dementia and Cognitive Impairment. in Neurology (eds. Clarke, C., Howard, R., Rossor, M. & Shorvon, S.) 289–336 (John Wiley & Sons, Ltd, 2016). doi:10.1002/9781118486160.ch8.
22.
Rossor, M. N., Fox, N. C., Mummery, C. J., Schott, J. M. & Warren, J. D. The diagnosis of young-onset dementia. The Lancet Neurology 9, 793–806 (2010).
23.
Schott, J. M., Fox, N. C. & Rossor, M. N. Assessment and investigation of the cognitively impaired adult. in Oxford Textbook of Cognitive Neurology and Dementia (eds. Husain, M. & Schott, J. M.) 221–230 (Oxford University Press, 2016). doi:10.1093/med/9780199655946.003.0021.
24.
Green, A. J. E. RT-QuIC: a new test for sporadic CJD. Practical Neurology (2018) doi:10.1136/practneurol-2018-001935.
25.
Collinge, J. Mammalian prions and their wider relevance in neurodegenerative diseases. Nature 539, 217–226 (2016).
26.
Mead, S. & Rudge, P. CJD mimics and chameleons. Practical Neurology 17, 113–121 (2017).
27.
Walker, Z., Possin, K. L., Boeve, B. F. & Aarsland, D. Lewy body dementias. The Lancet 386, 1683–1697 (2015).
28.
Halliday, G. M., Holton, J. L., Revesz, T. & Dickson, D. W. Neuropathology underlying clinical variability in patients with synucleinopathies. Acta Neuropathologica 122, 187–204 (2011).
29.
Barker, R. A. & Williams-Gray, C. H. Review: The spectrum of clinical features seen with alpha synuclein pathology. Neuropathology and Applied Neurobiology 42, 6–19 (2016).
30.
Bras, J. et al. Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. Human Molecular Genetics 23, 6139–6146 (2014).
31.
McKeith, I. G. et al. Diagnosis and management of dementia with Lewy bodies. Neurology 89, 88–100 (2017).
32.
Weil, R. S., Lashley, T. L., Bras, J., Schrag, A. E. & Schott, J. M. Current concepts and controversies in the pathogenesis of Parkinson’s disease dementia and Dementia with Lewy Bodies. F1000Research 6, (2017).
33.
Woollacott, I. O. C. & Rohrer, J. D. The clinical spectrum of sporadic and familial forms of frontotemporal dementia. Journal of Neurochemistry 138, 6–31 (2016).
34.
Gordon, E., Rohrer, J. D. & Fox, N. C. Advances in neuroimaging in frontotemporal dementia. Journal of Neurochemistry 138, 193–210 (2016).
35.
Ahmed, R. M. et al. Neuronal network disintegration: common pathways linking neurodegenerative diseases. Journal of Neurology, Neurosurgery & Psychiatry 87, 1234–1241 (2016).
36.
Fletcher, P. D. & Warren, J. D. Semantic Dementia: a specific network-opathy. Journal of Molecular Neuroscience 45, 629–636 (2011).
37.
Goll, J. C. et al. Non-verbal sound processing in the primary progressive aphasias. Brain 133, 272–285 (2010).
38.
Goll, J. C., Ridgway, G. R., Crutch, S. J., Theunissen, F. E. & Warren, J. D. Nonverbal sound processing in semantic dementia: A functional MRI study. NeuroImage 61, 170–180 (2012).
39.
Gorno-Tempini, M. L. et al. Classification of primary progressive aphasia and its variants. Neurology 76, 1006–1014 (2011).
40.
Grossman, M. The non-fluent/agrammatic variant of primary progressive aphasia. The Lancet Neurology 11, 545–555 (2012).
41.
Leyton, C. E. et al. Is the logopenic-variant of primary progressive aphasia a unitary disorder? Cortex 67, 122–133 (2015).
42.
Marshall, C. R. et al. Primary progressive aphasia: a clinical approach. Journal of Neurology 265, 1474–1490 (2018).
43.
Rohrer, J. D. et al. Word-finding difficulty: a clinical analysis of the progressive aphasias. Brain 131, 8–38 (2007).
44.
Rohrer, J. D. et al. Progressive logopenic/phonological aphasia: Erosion of the language network. NeuroImage 49, 984–993 (2010).
45.
Rohrer, J. D., Rossor, M. N. & Warren, J. D. Syndromes of nonfluent primary progressive aphasia: A clinical and neurolinguistic analysis. Neurology 75, 603–610 (2010).
46.
Rohrer, J. D., Sauter, D., Scott, S., Rossor, M. N. & Warren, J. D. Receptive prosody in nonfluent primary progressive aphasias. Cortex 48, 308–316 (2012).
47.
Warren, J. D., Rohrer, J. D. & Rossor, M. N. Frontotemporal dementia. BMJ 347, f4827–f4827 (2013).
48.
Lynch, D. S. et al. Clinical and genetic characterization of leukoencephalopathies in adults. Brain 140, 1204–1211 (2017).
49.
Inherited metabolic disease in adults: a clinical guide. (Oxford University Press, 2016).
50.
Devenney, E., Vucic, S., Hodges, J. R. & Kiernan, M. C. Motor neuron disease-frontotemporal dementia: a clinical continuum. Expert Review of Neurotherapeutics 15, 509–522 (2015).
51.
Strong, M. J. et al. Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 18, 153–174 (2017).
52.
Iranzo, A. et al. Neurodegenerative Disorder Risk in Idiopathic REM Sleep Behavior Disorder: Study in 174 Patients. PLoS ONE 9, (2014).
53.
Kielb, S. A., Ancoli-Israel, S., Rebok, G. W. & Spira, A. P. Cognition in Obstructive Sleep Apnea-Hypopnea Syndrome (OSAS): Current Clinical Knowledge and the Impact of Treatment. NeuroMolecular Medicine 14, 180–193 (2012).
54.
Mander, B. A., Winer, J. R., Jagust, W. J. & Walker, M. P. Sleep: A Novel Mechanistic Pathway, Biomarker, and Treatment Target in the Pathology of Alzheimer’s Disease? Trends in Neurosciences 39, 552–566 (2016).
55.
McCarter, S. J., St. Louis, E. K. & Boeve, B. F. Sleep Disturbances in Frontotemporal Dementia. Current Neurology and Neuroscience Reports 16, (2016).
56.
Ooms, S. & Ju, Y.-E. Treatment of Sleep Disorders in Dementia. Current Treatment Options in Neurology 18, (2016).
57.
Hardy, C. J. D. et al. Hearing and dementia. Journal of Neurology 263, 2339–2354 (2016).
58.
Livingston, G. et al. Dementia prevention, intervention, and care. The Lancet 390, 2673–2734 (2017).
59.
Goll, J. C., Crutch, S. J. & Warren, J. D. Central auditory disorders: toward a neuropsychology of auditory objects. Current Opinion in Neurology 23, 617–627 (2010).
60.
Husain, M. Oxford textbook of cognitive neurology and dementia. (Oxford University Press, 2016).
61.
Blennow, K., Hardy, J. & Zetterberg, H. The Neuropathology and Neurobiology of Traumatic Brain Injury. Neuron 76, 886–899 (2012).
62.
Smith, D. H., Johnson, V. E. & Stewart, W. Chronic neuropathologies of single and repetitive TBI: substrates of dementia? Nature Reviews Neurology 9, 211–221 (2013).
63.
McKee, A. C. et al. The spectrum of disease in chronic traumatic encephalopathy. Brain 136, 43–64 (2013).
64.
Fleminger, S. Head injury as a risk factor for Alzheimer’s disease: the evidence 10 years on; a partial replication. Journal of Neurology, Neurosurgery & Psychiatry 74, 857–862 (2003).
65.
Scott, G. et al. Amyloid pathology and axonal injury after brain trauma. Neurology 86, 821–828 (2016).
66.
Hereditary and sporadic beta-amyloidoses. https://www.bioscience.org/2013/v18/af/4173/fulltext.htm.
67.
Johnson, G. V. W. Tau phosphorylation in neuronal cell function and dysfunction. Journal of Cell Science 117, 5721–5729 (2004).
68.
Revesz, T. et al. Genetics and molecular pathogenesis of sporadic and hereditary cerebral amyloid angiopathies. Acta Neuropathologica 118, 115–130 (2009).
69.
Montine, T. J. et al. National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach. Acta Neuropathologica 123, 1–11 (2012).
70.
Thal, D. R. Neurodegeneration in Normal Brain Aging and Disease. Science of Aging Knowledge Environment 2004, pe26–pe26 (2004).
71.
Braak, H. & Braak, E. Staging of alzheimer’s disease-related neurofibrillary changes. Neurobiology of Aging 16, 271–278 (1995).
72.
Mirra, S. S. et al. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD): Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology 41, 479–479 (1991).
73.
Montine, T. J. et al. National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach. Acta Neuropathologica 123, 1–11 (2012).
74.
Dobson, R. & Alvares, D. The difficulties with vitamin B. Practical Neurology 16, 308–311 (2016).
75.
Jonathan Carr. Neurosyphilis. Practical Neurology 3, 328–341 (2003).
76.
Graus, F. et al. A clinical approach to diagnosis of autoimmune encephalitis. The Lancet Neurology 15, 391–404 (2016).
77.
Salvarani, C., Brown, R. D. & Hunder, G. G. Adult primary central nervous system vasculitis. The Lancet 380, 767–777 (2012).
78.
Halperin, J. J. et al. Practice guideline: Idiopathic normal pressure hydrocephalus: Response to shunting and predictors of response. Neurology 85, 2063–2071 (2015).
79.
Arash Asher. The effect of cancer treatment on cognitive function. undefined.
80.
Graus, F. et al. A clinical approach to diagnosis of autoimmune encephalitis. The Lancet Neurology 15, 391–404 (2016).
81.
Cognitive Impairment Associated with Cancer: A Brief Review. Innovations in Clinical Neuroscience 15, (2018).
82.
Haddow, L. J., Cartledge, J. D. & Manji, H. HIV and the brain: from AIDS to old age. Clinical Medicine 13, s24–s28 (2013).
83.
Nightingale, S., Michael, B. D., Defres, S., Benjamin, L. A. & Solomon, T. Test them all; an easily diagnosed and readily treatable cause of dementia with life-threatening consequences if missed. Practical Neurology 13, 354–356 (2013).
84.
HIV in the United Kingdom 2016 infographic. https://www.gov.uk/government/publications/hiv-in-the-united-kingdom.
85.
Itzhaki, R. F. et al. Microbes and Alzheimer’s Disease. Journal of Alzheimer’s Disease 51, 979–984 (2016).
86.
Nightingale, S. et al. Controversies in HIV-associated neurocognitive disorders. The Lancet Neurology 13, 1139–1151 (2014).
87.
Richard W. Price and Bruce J. Brew. The AIDS Dementia Complex. The Journal of Infectious Diseases 158, (1988).
88.
UK National Guidelines for HIV Testing 2008. https://www.bhiva.org/HIV-testing-guidelines.
89.
Zhou, L., Miranda-Saksena, M. & Saksena, N. K. Viruses and neurodegeneration. Virology Journal 10, (2013).
90.
De Chiara, G. et al. Infectious Agents and Neurodegeneration. Molecular Neurobiology 46, 614–638 (2012).
91.
Wendorf, K. A. et al. Subacute Sclerosing Panencephalitis: The Devastating Measles Complication That Might Be More Common Than Previously Estimated. Clinical Infectious Diseases 65, 226–232 (2017).
92.
Ghanem, K. G. REVIEW: Neurosyphilis: A Historical Perspective and Review. CNS Neuroscience & Therapeutics 16, e157–e168 (2010).
93.
Somasundaram, O. Neuro syphilis: Portrayals by Sir Arthur Conan Doyle. Indian Journal of Psychiatry 51, (2009).
94.
Hachinski, V. et al. National Institute of Neurological Disorders and Stroke–Canadian Stroke Network Vascular Cognitive Impairment Harmonization Standards. Stroke 37, 2220–2241 (2006).
95.
Gorelick, P. B. et al. Vascular Contributions to Cognitive Impairment and Dementia. Stroke 42, 2672–2713 (2011).
96.
Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. The Lancet 357, 169–175 (2001).
97.
Leys, D., Hénon, H., Mackowiak-Cordoliani, M.-A. & Pasquier, F. Poststroke dementia. The Lancet Neurology 4, 752–759 (2005).
98.
O’Brien, J. T. & Thomas, A. Vascular dementia. The Lancet 386, 1698–1706 (2015).